Last reviewed · How we verify
Short treatment with benznidazole
Short treatment with benznidazole is a Nitroimidazole antiparasitic Small molecule drug developed by Laboratorio Elea Phoenix S.A.. It is currently in Phase 3 development for Chagas disease (Trypanosoma cruzi infection), chronic phase. Also known as: Benznidazole 4 weeks.
Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and proteins of Trypanosoma cruzi, the parasite causing Chagas disease.
Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and proteins of Trypanosoma cruzi, the parasite causing Chagas disease. Used for Chagas disease (Trypanosoma cruzi infection), chronic phase.
At a glance
| Generic name | Short treatment with benznidazole |
|---|---|
| Also known as | Benznidazole 4 weeks |
| Sponsor | Laboratorio Elea Phoenix S.A. |
| Drug class | Nitroimidazole antiparasitic |
| Target | Trypanosoma cruzi DNA and proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Benznidazole is activated by parasite nitroreductase enzymes to form reactive intermediates that bind to and damage parasite DNA and proteins, leading to parasite death. It is effective against the acute phase of Chagas disease and has been studied for chronic phase treatment to reduce parasitemia and prevent disease progression. The short treatment regimen aims to optimize efficacy while minimizing cumulative toxicity.
Approved indications
- Chagas disease (Trypanosoma cruzi infection), chronic phase
Common side effects
- Peripheral neuropathy
- Rash
- Gastrointestinal disturbances
- Headache
- Bone marrow suppression
Key clinical trials
- Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age (PHASE3)
- Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients (PHASE3)
- Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease (PHASE3)
- Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short treatment with benznidazole CI brief — competitive landscape report
- Short treatment with benznidazole updates RSS · CI watch RSS
- Laboratorio Elea Phoenix S.A. portfolio CI
Frequently asked questions about Short treatment with benznidazole
What is Short treatment with benznidazole?
How does Short treatment with benznidazole work?
What is Short treatment with benznidazole used for?
Who makes Short treatment with benznidazole?
Is Short treatment with benznidazole also known as anything else?
What drug class is Short treatment with benznidazole in?
What development phase is Short treatment with benznidazole in?
What are the side effects of Short treatment with benznidazole?
What does Short treatment with benznidazole target?
Related
- Drug class: All Nitroimidazole antiparasitic drugs
- Target: All drugs targeting Trypanosoma cruzi DNA and proteins
- Manufacturer: Laboratorio Elea Phoenix S.A. — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Parasitology
- Indication: Drugs for Chagas disease (Trypanosoma cruzi infection), chronic phase
- Also known as: Benznidazole 4 weeks
- Compare: Short treatment with benznidazole vs similar drugs
- Pricing: Short treatment with benznidazole cost, discount & access